Roche (RHHBY) announced that the United States FDA has cleared its Elecsys pTau181 test, the only blood-based biomarker test indicated as an aid in the initial assessment for Alzheimer’s disease and other causes of cognitive decline in the primary-care setting. The Elecsys pTau181 test is intended for patients ages 55 and older presenting with signs, symptoms or complaints of cognitive decline. It measures phosphorylated Tau 181 protein in human plasma, a key biomarker for Alzheimer’s pathology, including amyloid plaque and tau aggregate pathology.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Roche to present 30 abstracts at ESMO, evERA study met co-primary endpoints
- Natera to present 14 studies to be presented at ESMO Congress
- Trump Weekly: Generics to be excluded from pharma tariff plan
- Trump Trade: GoodRx, others in talks with White House to join TrumpRx
- GoodRx, others in talks with White House to join TrumpRx, Reuters reports